(MDT) Medtronic Launches New Product for Complex Pinal Procedures

Medtronic Inc. (MDT) recently launched a new TSRH 3Dx Spinal System, which is a hook, rod and screw system used in complex spinal procedures. The system offers two screws designed to address multiple pathologies. The Multi Planar Adjusting (MPA) Screw gives surgeons the flexibility of a variable angle posted screw for targeted, controlled correction maneuvers. The OSTEOGRIP Screw enhances bone fixation by incorporating a dual-lead thread pattern that reduces toggle at the bone-screw interface.

The new pedicle screw system has a unique technology that addresses multiple spinal pathologies, from degenerative disc disease to spinal deformity. The product offers an alternative to patients for spinal stabilization with fusion. It works for patients suffering from degenerative spinal conditions, deformity, or injury of the thoracic, lumbar, and sacral spine. The TSRH Spinal System also provides Chromaloy rods and a minimally invasive capability.

We think that the new product will be widely accepted by orthopedic surgeons as a result of its unique features. This will expand Medtronic’s revenues in the Spinal and Biologics segment.
Medtronic is one of the world’s leading medical technology companies, specializing in implantable and interventional therapy devices and products. The company’s main competitors include St. Jude Medical (STJ) and Boston Scientific Corporation (BSX).

Medtronic’s management has a typical “ONE Medtronic" approach that encompasses the following goals: drive sustainable long-term growth of 9%−11% through innovation, focus on operating margins − increase by 300 to 400 basis points, EPS growth of 11%−14% and return a minimum of 40%−50% of free cash flow to shareholders annually, and align the organization for consistent execution. Medtronic’s fiscal first quarter results indicate that the company is well on track to achieve these goals.

Bernstein Research released their analysis of Medtronic Inc. (NYSE: MDT) and has a neutral stance for the stock with a price target of $40.

Bernie Schaeffer uses a combination of fundamental and technical and sentiment indicators to select his stock and options trades. Here's a long and a short idea from The Options Advisor.

"While Armstrong World Industries (NYSE: AWI) specializes in flooring, the shares are far from getting trampled underfoot.

"In fact, following a 319% rally off its March lows, AWI now sports a year-to-date gain of nearly 78%. What’s more, the shares have outperformed the S&P500 Index by some 62% on a relative-strength basis during the past 60 trading days.

"Currently, the shares are trending higher along solid support at their 10-day and 20-day moving averages, below which AWI has closed only once since mid-July.

"Sentiment is decidedly bearish on the security; the 10-day put/call ratio arrives at 5.8, as puts bought to open have nearly sextupled calls purchased during the past two weeks.

"Additionally, short interest accounts for more than 6% of AWI’s float. An unwinding of this pessimism should help propel the shares steadily higher. For options traders, we recommend buying the June 35 calls.

"St. Jude Medical (NYSE: STJ) has been a broad-market laggard lately, underperforming the SPX by 22% during the past 60 sessions.

"Weighing on the stock has been its 20-month moving average, which has been breached only once on a monthly closing basis since September 2008. Nevertheless, the Street’s outlook toward STJ remains sunny, with 14 out of 24 ranking analysts deeming the stock a 'buy' or better.

"Plus, the equity’s open intererest rate rests at 0.35, suggesting calls virtually triple puts among options slated to expire within three months. Amid the stock’s technical troubles, these bulls could abandon ship. 

"A round of downgrades or a reversal in sentiment in the options pits could exacerbate STJ’s challenges on the charts. For options traders, we recommend buying the April 40 puts."

(MDT) Medtronic, Inc Launches New Bone Grafter

(MDT) Medtronic Reports Enrollment in its Attain Success Trial

Medtronic, Inc. (MDT) recently launched MASTERGRAFT Strip - a new, highly flexible ceramic scaffold used in combination with a patient’s own bone for fusing multiple levels of the posterolateral spine, in the U.S. The strip is used by surgeons for a variety of bone grafting procedures.
 
MASTERGRAFT Strip is primarily used when the spine loses stability or its natural shape. The product offers a continuous latticework for longer grafting procedures at the back of the spine. It also enables maximization of the bony surface area contact and allows for continuous bone growth over large bony gaps. MASTERGRAFT Strip is available in unique lengths that eliminate the requirement of multiple strip units for a long fusion.
 
MASTERGRAFT Strip’s unique features and ease of handling during implantation makes it a preferred choice for spine surgeons. We therefore expect the product to increase the Spinal and Biologics business of Medtronic.

Medtronic is one of the world’s leading medical technology companies, specializing in implantable and interventional therapy devices and products. The company’s main competitors include St. Jude Medical (STJ) and Boston Scientific Corp. (BSX).

Medtronic’s management has a typical ‘ONE Medtronic’ approach that encompasses the following goals: drive sustainable long-term growth of 9%-11% through innovation; focus on operating margins -- increase by 300 to 400 basis points; EPS growth of 11%-14% and return a minimum of 40%-50% of free cash flow to shareholders annually; and align the organization for consistent execution. Medtronic’s fiscal first quarter results indicate that the company is well on track in achieving these goals.